Alzheimer’s: latest news - Page 2 of 2 - GoINPHARMA
Sunday, 18 November 2018 - 2:55

Alzheimer’s

Alzheimer’s, new research suggests new disease progression model

A research focusing on the molecular mechanisms through which Alzheimer’s disease spreads across the brain has been published. The study was conducted by Nathan Spreng, Cornell University, in collaboration with Taylor Schmitz, University of Cambridge. The article, titled “Basal forebrain…

MSD publishes data on verubecestat, investigational Alzheimer’s drug

MSD announced the publication on the journal Science Translational Medicine of data about verubecestat, an investigational BACE1 (beta-site amyloid precursor protein cleaving enzyme 1) inhibitor, being developed as a potential treatment of Alzheimer’s disease. The results emerged from a Phase…

Alzheimer’s, Eisai assesses two products in several clinical trials

Eisai announced that two clinical trials designed to evaluate two investigational Alzheimer’s products have commenced. The former is a Phase II trial, named Study 202: it will test E2006 (lemborexant) in patients with mild-to-moderate Alzheimer’s disease and ISWRD (Irregular Sleep-Wake…

Alzheimer, first positive Phase III results for amyloid treatment

Results from analyses of Phase III data for tramiprosate, an investigational amyloid-targeted drug, in patients with mild to moderate Alzheimer’s disease have been published on The Journal of the Prevention of Alzheimer’s Disease (JPAD). These analyses evaluated patient subgroups based…

Alzheimer’s, experts outline prospects for 2025

The journal Alzheimer’s Research & Therapy has recently published an interesting review conducted by a panel of experts in order to check the state of the art of Alzheimer’s research. Moreover, the review formulates hypotheses related to the scenario in…

Expert sees good chances of success for Lilly’s Alzheimer’s drug

Analysts from BMO have examined the chances of success for a drug currently tested in Alzheimer’s disease and in advanced-stage clinical development – Eli Lilly’s solanezumab. They have made reference to evaluations by one of the leading Alzheimer’s disease experts,…

Alzheimer’s, Phase III trial of Lundbeck’s candidate fails

Lundbeck has reported the failure of a Phase III trial for its candidate to address Alzheimer’s disease. The drug has not reached, with neither dose, a result different from that obtained through the placebo. Lundbeck has conducted the research in…

The rich big pharma pipeline against Alzheimer’s

Finding a way to cure Alzheimer’s disease, a condition affecting over 45 million people worldwide, is probably one of the main, but also hardest challenges for big pharma companies. In the pipelines of those companies carrying out research in this…